Skip to main content
OpenTrials
Completed

NCT Number: NCT04246788

Intensive Robotic Rehabilitation in Children With Hemiparesia Using GEOSYSTEM

Cerebral palsy is the most frequent motor deficiency in children. Among other, it can leads to spastic diplegia or hemiplegia. Walking abilities is an important skill to the families' point of view in term of independence in curent life. Improving the walking parameters has been the main objective in several studies of rehabilitation. The G-EO system is a last generation robot assisting gait training that can adjust cadence, walk lengh, ankle and hip angles and other walking parameters to movement captation. Its superiority in terms of walking abilities has been demonstrated in adults with stroke sequelae. Only one study was realized in pediatric patients with spastic diplegia with promising results. The investigators hypothesize that intensive robot-assited gait training using the G-EO system in hemiplegic children can improve their walking abilities.

Completed

Looking for future studies?

Notify Me

Key information

Age range

4 year–18 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

CHU Clermont Ferrand

Clermont-Ferrand, Auvergne, 63000, France

About this study

Objective :

Primary objective: To evaluate walking velocity with the GRAIL (gait real-time analysis and interactive lab) after intensive robot-assisted gait training using the G-EO system in hemiplegic children.

Secondary objectives :Other parameters that will be evaluate include:

  • Endurance on the 6 minute walking test
  • Joint angles and muscular contraction on the GRAIL
  • Number of steps and travelled distance /24h, cardiac frequency and quality of sleep using actimeter bracelet
  • Motor functions using the GMFM (Gross Motor Function Measure)
  • Spasticity using the modified Ashworth scale
  • The functional independence using the Functional Independence Measure (FIM™) for children,
  • The quality of life using the Patient Global Impression (PGI-I)
  • Muscular strength using the muscular testing cotation scale
  • The musculo-squeletal and adipose composition using the peripherical quantitative computed tomography (pQCT)
  • The cerebral area activation using functional MRI Study Type: Controlled randomized pilote study Number of centres: Monocentric study, University hospital of Clermont-Ferrand

Study procedure:

  • Experimental group: 5 sessions per week of 30 minutes of robot-assisted rehabilitation with the G-EO system during two weeks
  • Control group : 3 sessions per week of 30 minutes of classical physiotherapy during two weeks

Study evaluation:

T0 : before rehabilitation :

  • Actimeter for 24h
  • 6 min walking test
  • GRAIL
  • Modified Ashworth scale
  • FIM for children
  • GMFM
  • Muscular testing scale
  • pQCT
  • fMRI

T1 : one month after rehabilitation :

  • idem T0
  • PGI-I questionnary Principal judgement criteria: Walking velocity Secondary judgement criteria: endurance, joint angles, number of steps and travelled distance per 24h, quality of sleep, cardiac frequency, spasticity, functional independence, motor functions, muscular strength, musculo-squeletal and adipose composition, brain activated areas.

Number of subjects:

  • 20 patients in the experimental group
  • 20 patients in the control group All patients enrolled in the control group will benefit of the GEOsystem rehabilitation at the end of the protocole

Inclusion criteria

Hemiplegic children aged from 4 to 18 years, with a GMFCS (Gross Motor Function Classification System) score between I and III with lower limb involvement. Children must walk alone with or without aid at least 10 meters, must have acquired sitting position, must be able to understand simple orders to follow the rehabilitation program.

Non inclusion criteria:

No lower limb involvement, spasticity = 4 on the modified Ashworth scale, severe cardiorespiratory disease forbidding the rehabilitation program, orthopedic surgery or botulinic toxin injections in the last 6 months before the beginning of the study.

Study calendar:

  • Starting inclusions: March 2020
  • Experimental procedure: March 2020 to March 2021
  • Data analyses and synthesis: April 2021 to Dember 2021

Statistical analyses Statistical analysis will be performed using Stata 13 software (Stata-Corp, College Station, TX) by an experimented statistician (Bruno Pereira) working in the university hospital of Clermont-Ferrand. A type-I error set at α=0.05 will be considered. Monovariate and multivariate analyses considering age as a covariable will be performed.

Ethical considerations This study has already been presented at the local ethical committee and will be presented in July 2019 at the national " comité de protection des personnes ". Written informed consent from both parents will be collected at the inclusion. This study will be in agreement with the declaration of Helsinki and the current regulations of clinical trials. It will be declared on the internet site "clinicaltrials.gov".

Expected results :

Intensive robot-assisted gait training using the G-EO system may improve the walking abilities in children with infantile hemiplegia and consequently improve their independence and quality of life. Musculo-squeletal parameters and profile of cerebral activated areas involved in praxia may also be modified by this intensive rehabilitation.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Hemiplegic children aged from 4 to 18 years
  • GMFCS (Gross Motor Function Classification System) score between I and III with lower limb involvement.
  • Children must walk alone with or without aid at least 10 meters, must have acquired sitting position, must be able to understand simple orders to follow the rehabilitation program.
  • Free and informed consent of holders of parental authority and of the patient
  • Affiliated to the social security system

Exclusion criteria

  • No lower limb involvement,
  • spasticity = 4 on the modified Ashworth scale,
  • severe cardiorespiratory disease forbidding the rehabilitation program,
  • orthopedic surgery or botulinic toxin injections in the last 6 months before the beginning of the study.

Treatment and study plan

Intensive robotic rehabilitation

Other

5 sessions per week of 30 minutes of robot-assisted rehabilitation with the G-EO system during two weeks

classical physiotherapy

Other

3 sessions per week of 30 minutes of classical physiotherapy during two weeks

Primary outcomes

  1. Gait speed

    Time frame: day 1

    gait speed assessed during a gait assessment session using the GRAIL system

  2. Gait speed

    Time frame: day 21

    gait speed assessed during a gait assessment session using the GRAIL system

  3. Gait speed

    Time frame: day 51

    gait speed assessed during a gait assessment session using the GRAIL system

Secondary outcomes

  1. 6 min. walk test (6-WT)

    Time frame: day 1

    endurance evaluation by 6 min. walk test (6-WT)

  2. 6 min. walk test (6-WT)

    Time frame: day 21

    endurance evaluation by 6 min. walk test (6-WT)

  3. 6 min. walk test (6-WT)

    Time frame: day 51

    endurance evaluation by 6 min. walk test (6-WT)

  4. joint angles

    Time frame: day 1

    Joint amplitudes measured during gait assessment with the GRAIL

  5. joint angles

    Time frame: day 21

    Joint amplitudes measured during gait assessment with the GRAIL

  6. joint angles

    Time frame: day 51

    Joint amplitudes measured during gait assessment with the GRAIL

  7. number of steps per 24h

    Time frame: day 1

    Number of steps per 24h, measured using a wristband actimeter which will be given to each child for 24 hours

  8. number of steps per 24h

    Time frame: day 21

    Number of steps per 24h, measured using a wristband actimeter which will be given to each child for 24 hours

  9. number of steps per 24h

    Time frame: day 51

    Number of steps per 24h, measured using a wristband actimeter which will be given to each child for 24 hours

  10. travelled distance

    Time frame: day 1

    distance traveled per 24 hours, per 24h, measured using a wristband actimeter which will be given to each child for 24 hours

  11. travelled distance

    Time frame: day 21

    distance traveled per 24 hours, per 24h, measured using a wristband actimeter which will be given to each child for 24 hours

  12. travelled distance

    Time frame: day 51

    distance traveled per 24 hours, per 24h, measured using a wristband actimeter which will be given to each child for 24 hours

  13. quality of sleep: wristband actimeter

    Time frame: day 1

    quality of sleep per 24 hours, per 24h, measured using a wristband actimeter which will be given to each child for 24 hours

  14. quality of sleep: wristband actimeter

    Time frame: day 21

    quality of sleep per 24 hours, per 24h, measured using a wristband actimeter which will be given to each child for 24 hours

  15. quality of sleep: wristband actimeter

    Time frame: day 51

    quality of sleep per 24 hours, per 24h, measured using a wristband actimeter which will be given to each child for 24 hours

  16. cardiac frequency

    Time frame: day 1

    heart rate per 24 hours, per 24h, measured using a wristband actimeter which will be given to each child for 24 hours

  17. cardiac frequency

    Time frame: day 21

    heart rate per 24 hours, per 24h, measured using a wristband actimeter which will be given to each child for 24 hours

  18. cardiac frequency

    Time frame: day 51

    heart rate per 24 hours, per 24h, measured using a wristband actimeter which will be given to each child for 24 hours

  19. Evaluation of spasticity

    Time frame: day 1

    Evaluation of spasticity by the modified Ashworth scale

  20. Evaluation of spasticity

    Time frame: day 21

    Evaluation of spasticity by the modified Ashworth scale

  21. Evaluation of spasticity

    Time frame: day 51

    Evaluation of spasticity by the modified Ashworth scale

  22. functional independence

    Time frame: day 1

    Overall functional independence assessed with the MIF-Môme autonomy scale

  23. functional independence

    Time frame: day 21

    Overall functional independence assessed with the MIF-Môme autonomy scale

  24. functional independence

    Time frame: day 51

    Overall functional independence assessed with the MIF-Môme autonomy scale

  25. motor functions

    Time frame: day 1

    Overall motor function evaluated with the EMFG

  26. motor functions

    Time frame: day 21

    Overall motor function evaluated with the EMFG

  27. motor functions

    Time frame: day 51

    Overall motor function evaluated with the EMFG

  28. muscular strength

    Time frame: day 1

    Muscle strength will be measured with a quotation scale (1 to 5) for manual muscle testing

  29. muscular strength

    Time frame: day 21

    Muscle strength will be measured with a quotation scale (1 to 5) for manual muscle testing

  30. muscular strength

    Time frame: day 51

    Muscle strength will be measured with a quotation scale (1 to 5) for manual muscle testing

  31. Body composition measurements

    Time frame: day 21

    fat body mass

  32. Body composition measurements

    Time frame: day 51

    fat body mass

  33. Body composition measurements

    Time frame: day 21

    lean body mass

  34. Body composition measurements

    Time frame: day 51

    lean body mass

  35. brain activated areas

    Time frame: day 21

    Functional brain connectivity analyzes by functional brain MRI

  36. brain activated areas

    Time frame: day 51

    Functional brain connectivity analyzes by functional brain MRI

Sponsors and collaborators

Lead sponsor

University Hospital, Clermont-Ferrand

Other

Collaborators

  • Université d'Auvergne

Registry information

Acronym: RIPHIGEO

Important dates

Study start
2020
Primary completion
2021
Study completion
2021
First posted
Jan 29, 2020
Registry last updated
Jan 11, 2022

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.